ClinicalTrials.gg
CompletedNCT07712731Updated Aug 3, 2026

HPP737 in Adult Patients With Plaque Psoriasis

A Phase 3 interventional study of HPP737 and Placebo matching HPP737 in Psoriasis, sponsored by Newsoara Biopharma Co., Ltd.. Completed at 60 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Newsoara Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Apr 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
18th of 182
607 · median 171
Started
2025
with 35 others
Phase 3
58 of 206
16 open now
Registered
197th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 18th largest by enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 58 in phase 3, and was the 197th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are:

Does drug HPP737 improve psoriasis severity compared to an active control drug, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score and other standardized assessments? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to an active control drug (a positive drug comparator) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis.

This is a multicenter, randomized, double-blind, double-dummy, active-controlled Phase III clinical trial. Participants will:

Take drug HPP737 or an active control drug orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) The trial plans to enroll approximately 606 participants across about 61 centers in China. Eligible participants are adults aged 18 years and older with a confirmed diagnosis of stable moderate-to-severe plaque psoriasis for at least 6 months.

Read the detailed description

This is a multicenter, randomized, double-blind, double-dummy, active parallel-controlled Phase III clinical trial evaluating the efficacy and safety of oral HPP737 in adult patients with moderate-to-severe chronic plaque psoriasis. The study is sponsored by Newsoara Biopharma Co., Ltd. (Shanghai) and has been approved by the National Medical Products Administration (NMPA) .

HPP737 is a novel, potent, and selective oral phosphodiesterase type 4 (PDE4) inhibitor in development for the treatment of psoriasis. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators, making it a validated therapeutic target for inflammatory diseases such as psoriasis. Preclinical and early clinical data indicate that HPP737 has demonstrated potent inhibition of interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α) production. HPP737 is designed to preferentially inhibit PDE4B, which is associated with anti-inflammatory activity, while limiting PDE4D engagement, which is believed to drive dose-limiting side effects, such as gastrointestinal distress. In Phase I studies, HPP737 was generally well-tolerated with a favorable safety profile.

Study Design: This study consists of three periods: a Screening Period, a Treatment Period, and a Safety Follow-up Period.

Screening Period (Day -14 to Day -1): Potential participants undergo screening procedures to assess eligibility based on inclusion and exclusion criteria.

Treatment Period (Week 0 to Week 16): Eligible participants are randomized in a 2:1 ratio to receive one of the following double-blind, double-dummy treatments for 16 weeks:

HPP737 20 mg orally once daily (experimental group, n≈404) Apremilast (active comparator) orally twice daily according to its approved dosing regimen (active comparator group, n≈202) Safety Follow-up Period (14 days after last dose): Following the completion of the 16-week treatment period, participants enter a safety follow-up period. This follow-up visit occurs 14 days after the last dose of study medication.

Study Population: Approximately 606 participants are planned to be enrolled in China. Eligible participants are adults aged ≥18 years with a confirmed clinical diagnosis of stable moderate-to-severe chronic plaque psoriasis and a history of psoriasis of at least 6 months.

Primary Objectives:

  1. To evaluate the efficacy of HPP737 20 mg compared with apremilast in patients with moderate-to-severe chronic plaque psoriasis, as measured by the proportion of participants achieving at least of a reduction of 75% in Psoriasis Area and Severity Index (PASI) (PASI 75) at Week 16.
  2. To evaluate the efficacy of HPP737 20 mg compared with apremilast in patients with moderate-to-severe chronic plaque psoriasis, as measured by the proportion of participants achieving a static Physician's Global Assessment (sPGA) score of "clear" (0) or "almost clear" (1) at Week 16.

The study is conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol has been reviewed and approved by the institutional review boards or ethics committees of all participating sites.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Moderate to severe plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must voluntarily sign the form prior to the initiation of any trial-related procedures, be able to communicate effectively with the investigators, and understand and comply with the requirements of this trial;
  • Age at the time of signing the informed consent form: age ≥18 years, regardless of sex;
  • Clinically diagnosed patients with stable plaque psoriasis (Zhendingxing Banquzhuang Yinxie Bing), with a psoriasis history of ≥6 months before randomization;
  • Diagnosed with moderate to severe plaque psoriasis and meeting the following criteria at screening: 1) PASI (Psoriasis Area and Severity Index), score ≥10; and sPGA (Static Physician's Global Assessment) score ≥3; and BSA (Body Surface Area) score ≥10%
  • (BMI): 18 kg/m2 ≤ BMI ≤ 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Presence of other forms of psoriasis (e.g., guttate psoriasis, pustular psoriasis, erythrodermic psoriasis) diagnosed at screening, in addition to chronic plaque psoriasis;
  • Patients with drug-induced psoriasis (including but not limited to newly onset or exacerbated psoriasis caused by β-blockers [beta-receptor blockers], calcium channel blockers, or lithium preparations)
  • Subjects with other skin diseases that may interfere with clinical assessment (such as severe bacterial, fungal, or viral skin infections), chronic diarrhea, severe gastrointestinal diseases (such as active peptic ulcer, gastrointestinal tract disorders, etc.), or a history of inflammatory bowel disease (Crohn's disease, ulcerative colitis, etc.), or other active inflammatory diseases (mixed connective tissue disease, idiopathic inflammatory myopathy, etc.);
  • History of congenital or acquired immunodeficiency;
  • Severe infection or systemic infection within 4 weeks prior to randomization, requiring oral and/or intravenous anti-infective therapy; or hospitalization due to infection;
  • Medical history, symptoms, and examination results during screening indicating that the subject has active tuberculosis (TB); Note: Subjects with a negative T-cell test for Mycobacterium tuberculosis infection (T-SPOT test) during the screening period are eligible for inclusion in this study. Subjects with a positive T-SPOT result during the screening period are required to undergo TB-related clinical evaluation (TB-related clinical evaluations conducted within 12 weeks prior to randomization may be directly utilized for assessment). If the TB-related clinical evaluation confirms active tuberculosis, the subject shall not be enrolled in this study; if the evaluation confirms non-active tuberculosis, the subject may be included. If the study center is unable to perform the T-SPOT test, an interferon-gamma release assay (IGRA) may also be used for TB screening, and the handling of IGRA results should follow the same procedures as for the T-SPOT test.
  • History of moderate to severe heart failure ( [NYHA] functional classification ≥ Class III), or occurrence of cardiovascular or cerebrovascular events or other serious events within 3 months prior to randomization, as judged by the investigator to be unsuitable for participation in this clinical trial;
  • History of in any organ system within 5 years prior to randomization, except for malignancies with low risk of and death, such as adequately treated carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin, etc.;
  • History of depression and/or suicidal ideation or any suicidal behavior at screening or baseline based on Columbia-Suicide Severity Rating Scale (C-SSRS) assessment (Appendix 6). If the subject answers "Yes" to any question on the C-SSRS questionnaire, or if the investigator assesses clinical risk, these subjects will be excluded;
  • Presence of clinically severe, progressive, or uncontrolled diseases during the screening period, including but not limited to the respiratory system, cardiovascular system, endocrine system, hematological system, skeletal system, and nervous system, where participation in the trial may pose unacceptable risk to the subject or interfere with interpretation of data, as assessed by the investigator;
  • Use of the following psoriasis (Yinxie Bing) treatments/medications prior to randomization: 1) Within 2 weeks prior to randomization, the subject has received topical treatment for psoriasis, such as , vitamin D3 derivatives, or retinoids. However, subjects are permitted to use the following topical treatments: non-medicated shampoos and emollients (i.e., those not containing glucocorticoids or vitamin D3 derivatives). Within 4 weeks prior to randomization, the subject has received phototherapy/photochemotherapy (including but not limited to psoralen and ultraviolet A (PUVA) phototherapy, ultraviolet B (UVB)) or non-biologic systemic therapies (including but not limited to systemic glucocorticoids, leflunomide, cyclophosphamide, azathioprine, methotrexate, cyclosporin, retinoids, mycophenolate mofetil, traditional Chinese medicines for the treatment of psoriasis, or other small-molecule targeted agents for the treatment of psoriasis). Tumor necrosis factor-α (TNF-α) antagonists: (1) Use of a TNF-α antagonist (e.g., adalimumab, infliximab, golimumab, etanercept, certolizumab pegol) within a specified period prior to randomization (such as within 12 weeks before randomization); (2) or history of prior use of two or more TNF-α antagonists before randomization; 4) Within 24 weeks prior to randomization, the subject has used other biologic agents, including but not limited to IL-17 inhibitors, IL-23 inhibitors, or IL-12/IL-23 inhibitor class drugs.
  • Receipt of a within 12 weeks prior to randomization, or planned receipt of a live attenuated vaccine during the trial period;
  • Subjects who previously had poor efficacy with other PDE4 (phosphodiesterase-4) inhibitors (such as apremilast, Hemay005, etc.)
  • Participation in and receipt of any interventional clinical trial treatment within 1 month prior to randomization;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
607 participants (actual)

Study arms

  • Experimental
    HPP737 20mg

    Specification:10mg; Participants receive HPP737 20 mg orally once daily for 16 weeks.

    Drug: HPP737 · Drug: Placebo matching Apremilast

  • Active comparator
    Aprmilast 30mg Bid

    Participants receive Apremilast for 16 weeks. According to product label, 5-day dose titration is required: Day 1: 10 mg in the morning; Day 2: 10 mg in the morning and 10 mg in the evening; Day 3: 10 mg in the morning and 20 mg in the evening; Day 4: 20 mg in the morning and 20 mg in the evening; Day 5: 20 mg in the morning and 30 mg in the evening; Day 6 and thereafter: 30 mg twice daily (morning and evening, approximately 12 hours apart).

    Drug: Placebo matching HPP737 · Drug: Apremilast

Interventions

  • DrugHPP737

    HPP737 capsules for oral administration.

  • DrugPlacebo matching HPP737

    Placebo capsules matching HPP737 for oral administration.

    Also known as: Placebo

  • Apremilast tablets for oral administration.

    Also known as: Otezla

  • DrugPlacebo matching Apremilast

    Placebo tablets matching Apremilast for oral administration.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75);

    Time frame: From enrollment to end of treatment at 16 weeks

  2. To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)"

    Time frame: From enrollment to end of treatment at 16 weeks

Secondary outcomes

  1. To evaluate proportion of subjects achieving PASI 75 response at Week 1, 2, 4, 8, and 12;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, and 12 weeks

  2. To evaluate proportion of subjects achieving at least a 50% reduction in PASI (PASI 50) at Week 1, 2, 4, 8, 12, and 16;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks

  3. To evaluate proportion of subjects achieving at least a 90% reduction in PASI (PASI 90) at Week 1, 2, 4, 8, 12, and 16;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks

  4. To evaluate proportion of subjects achieving at least a 100% reduction in PASI (PASI 100) at Week 1, 2, 4, 8, 12, and 16;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks.

  5. To evaluate change from baseline in PASI score, and percent change from baseline in PASI score at Week 1, 2, 4, 8, 12, and 16;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks

  6. To evaluate proportion of subjects achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)" at week 1, 2, 4, 8, and 12;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, and 12 weeks

  7. To evaluate change from baseline in Body Surface Area (BSA) score, and percent change from baseline in BSA score at Week 1, 2, 4, 8, 12, and 16;

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks

  8. To evaluate change from baseline in Dermatology Life Quality Index (DLQI) score, and percent change from baseline in DLQI score Week 1, 2, 4, 8, 12, and 16.

    Time frame: From enrollment to end of treatment at 1, 2, 4, 8, 12, and 16 weeks.

  9. To evaluate incidence and severity of adverse events

    Time frame: From ICF signed to end of study follow-up at 18 weeks.

  10. To evaluate pharmacokinetic characteristics of subjects at Week 0, Week 4, Week 8, and Week 16

    Time frame: From enrollment (Week 0) to end of treatment at 4,8,16 weeks.

07

Study locations

60 sites
  • Inner Mongolia Baogang Hospital
    Baotou, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • Cangzhou People's Hospital
    Cangzhou, China
  • The Second Hospital of Jilin University
    Changchun, China
  • Changde First People's Hospital
    Changde, China
  • Third Xiangya Hospital of Central South University
    Changsha, China
  • The Second People's Hospital of Changzhi
    Changzhi, China
  • Affiliated Hospital of Chengde Medical College
    Chengde, China
  • Chengdu Second People's Hospital
    Chengdu, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Dalian Dermatology Hospital
    Dalian, China
  • Dermatology Hospital, Southern Medical University
    Guangzhou, China
  • Guangzhou First People's Hospital
    Guangzhou, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, China
  • Hainan Fifth People's Hospital
    Haikou, China
  • Hangzhou First People's Hospital
    Hangzhou, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, China
  • Dermatology Hospital, Shandong First Medical University
    Jinan, China
  • Jinan Central Hospital
    Jinan, China
  • Shandong Provincial Hospital
    Jinan, China
  • Jingzhou Central Hospital
    Jingmen, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, China
  • Lianyungang First People's Hospital
    Lianyungang, China
  • Liaocheng People's Hospital
    Liaocheng, China
  • Jiangxi Provincial Dermatology Hospital
    Nanchang, China
  • Second Affiliated Hospital of Nanchang University
    Nanchang, China
  • Hospital of Dermatology, Chinese Academy of Medical Sciences
    Nanjing, China
  • First Affiliated Hospital of Ningbo University
    Ningbo, China
  • Qingdao Traditional Chinese Medicine Hospital (Hai Ci Hospital)
    Qingdao, China
  • Qujing First People's Hospital
    Qujing, China
  • Huashan Hospital, Fudan University
    Shanghai, China
  • Shanghai Skin Disease Hospital
    Shanghai, China
  • Affiliated Central Hospital of Shenyang Medical College
    Shengyang, China
  • Zhongyi Northeast International Hospital Co., Ltd.
    Shengyang, China
  • Liaoning Provincial People's Hospital
    Shenyang, China
  • Shenyang Hospital of Integrated Traditional Chinese and Western Medicine
    Shenyang, China
  • Shenzhen Second People's Hospital
    Shenzhen, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, China
  • Shiyan People's Hospital
    Shiyan, China
  • Suining Central Hospital
    Suining, China
  • First Hospital of Shanxi Medical University
    Taiyuan, China
  • Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
    Tianjin, China
  • Meihekou Central Hospital
    Tonghua, China
  • First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
  • Wuhan No.1 hospital
    Wuhan, China
  • Second Affiliated Hospital of Wannan Medical College
    Wuhu, China
  • Affiliated Hospital of Jiangsu University
    Wuxi, China
  • Wuxi Second People's Hospital
    Wuxi, China
  • Xingtai People's Hospital
    Xingtai, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
  • Yancheng First People's Hospital
    Yancheng, China
  • General Hospital of Ningxia Medical University
    Yinchuan, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Apr 2026, 11 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 17, 2026
StartActual
Apr 18, 2025
Primary completionActual
Apr 1, 2026
CompletionActual
Apr 1, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712731
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Apr 18, 2025
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Last update
Aug 3, 2026

Study contacts

Jianzhong Zhang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HPP737

Start the discussion